Breaking News, Collaborations & Alliances

Janssen, TenNor Enter NTM Research Pact

To leverage TenNor’s multitargeting drug conjugation platform to discover new therapies to treat nontuberculous mycobacteria diseases.

By: Contract Pharma

Contract Pharma Staff

TenNor Therapeutics (Suzhou) Ltd., a biopharmaceutical company dedicated to products for the treatment of diseases associated with bacterial infections and dysbioses, has entered into a research collaboration with Janssen Pharmaceuticals, Inc., to leverage a multitargeting drug conjugation platform developed by TenNor to discover new therapies to treat nontuberculous mycobacteria (NTM) diseases. The agreement was facilitated by Johnson & Johnson Innovation LLC.   NTM are mycobacteria other...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters